Pediatrics Doctors in Caldwell, ID Accepting Medicare

7 Pediatrics doctors found. Showing 1 - 7

Jee Hur, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 315 E Elm Street, Ste 100, Caldwell, ID 83605 Phone: 208-459-7415    Fax: 208-453-3307

Natasha Miller, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 315 E Elm, Ste 100, Caldwell, ID 83605 Phone: 208-459-7415    Fax: 208-453-3307

Amanda Lee, Pediatrics Medicare: Medicare Enrolled Practice Location: 1620 S Kimball Ave, Caldwell, ID 83605 Phone: 208-505-2950

Merle L. Keller Iii, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 315 E. Elm Ste 100, Caldwell, ID 83605 Phone: 208-302-7100    Fax: 208-302-7155

Matthew S Brown, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 315 E Elm St Ste 100, Caldwell, ID 83605 Phone: 208-302-7100    Fax: 208-302-7189

Timothy Curtis Borup, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 315 E Elm St Ste 100, Caldwell, ID 83605 Phone: 208-302-7100    Fax: 208-302-7155

David Babbel, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 315 E Elm St, Caldwell, ID 83605 Phone: 208-302-7100    Fax: 208-302-7155

News Archive

ACMG advocates sharing of laboratory and clinical genomic data to improve genetic health care

There are an estimated 5,000 - 7,000 rare genetic diseases, each of which can vary dramatically and be caused by a multitude of different genetic changes.

Biohit Oyj to distribute Dynex automated ELISA systems with Gastropanel

Finnish healthcare company Biohit Oyj and American company Dynex Technologies, Inc. have signed an agreement for the distribution of the two-microplate DS2®, four-microplate DSX® and 12-microplate Agility® automated ELISA (enzyme-linked immunosorbent assay) processing systems, for use with the Biohit Oyj GastroPanel.

FDA: New drug Tivicay approved to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply.

Takeda and Cardurion announce creation of new cardiovascular development partnership

Takeda Pharmaceutical Company Limited and Cardurion Pharmaceuticals today announced the creation of a new cardiovascular development partnership.

Research shows oral contraceptive use over three years could be a risk factor for glaucoma

Research presented today, at the 117th Annual Meeting of the American Academy of Ophthalmology in New Orleans, has found that women who have taken oral contraceptives for three or more years are twice as likely to suffer from glaucoma, one of the leading causes of blindness which affects nearly 60 million worldwide. The researchers caution gynecologists and ophthalmologists to be aware of the fact that oral contraceptives might play a role in glaucomatous diseases, and inform patients to have their eyes screened for glaucoma if they also have other risk factors.

Read more Medical News

› Verified 1 days ago